Skip to main content

Table 1

From: Clinical and economic efficiency to reduce dose etanercept and adalimumab in patients with rheumatoid arthritis

  BASELINE 3 months (p baseline-3m) 6 months (p 3m-6m) INFERENCE
VAS (mm)     
-ETN 21.00±16.63 26.50±18.56 (p = 0.048) 23.89±17.28 (p = 0.22) p = 0.89
-ADA 30.00±20.00 38.67±18.03 (p = 0.49) 20.00±19.36 (p = 0.54) p = 0.36
HAQ     
-ETN 0.48±0.50 0.61±0.45 (p = 0.33) 0.49±0.40 (p = 0.34) p = 0.67
-ADA 1.33±0.21 1.66±0.28 (p = 0.19) 1.93±0.26 (p = 0.25) p = 0.003
DAS28     
-ETN 2.15±0.45 2.74±0.85 (p = 0.056) 2.41±0.77 (p = 0.005) p = 0.20
-ADA 2.13±0.47 3.85±1.07 (p = 0.97) 2.98±1.03 (p = 0.005) p = 0.005